1
|
Karamanavi E, McVey DG, van der Laan SW, Stanczyk PJ, Morris GE, Wang Y, Yang W, Chan K, Poston RN, Luo J, Zhou X, Gong P, Jones PD, Cao J, Kostogrys RB, Webb TR, Pasterkamp G, Yu H, Xiao Q, Greer PA, Stringer EJ, Samani NJ, Ye S. The FES Gene at the 15q26 Coronary-Artery-Disease Locus Inhibits Atherosclerosis. Circ Res 2022; 131:1004-1017. [PMID: 36321446 PMCID: PMC9770135 DOI: 10.1161/circresaha.122.321146] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 10/16/2022] [Accepted: 10/17/2022] [Indexed: 12/05/2022]
Abstract
BACKGROUND Genome-wide association studies have discovered a link between genetic variants on human chromosome 15q26.1 and increased coronary artery disease (CAD) susceptibility; however, the underlying pathobiological mechanism is unclear. This genetic locus contains the FES (FES proto-oncogene, tyrosine kinase) gene encoding a cytoplasmic protein-tyrosine kinase involved in the regulation of cell behavior. We investigated the effect of the 15q26.1 variants on FES expression and whether FES plays a role in atherosclerosis. METHODS AND RESULTS Analyses of isogenic monocytic cell lines generated by CRISPR (clustered regularly interspaced short palindromic repeats)-mediated genome editing showed that monocytes with an engineered 15q26.1 CAD risk genotype had reduced FES expression. Small-interfering-RNA-mediated knockdown of FES promoted migration of monocytes and vascular smooth muscle cells. A phosphoproteomics analysis showed that FES knockdown altered phosphorylation of a number of proteins known to regulate cell migration. Single-cell RNA-sequencing revealed that in human atherosclerotic plaques, cells that expressed FES were predominately monocytes/macrophages, although several other cell types including smooth muscle cells also expressed FES. There was an association between the 15q26.1 CAD risk genotype and greater numbers of monocytes/macrophage in human atherosclerotic plaques. An animal model study demonstrated that Fes knockout increased atherosclerotic plaque size and within-plaque content of monocytes/macrophages and smooth muscle cells, in apolipoprotein E-deficient mice fed a high fat diet. CONCLUSIONS We provide substantial evidence that the CAD risk variants at the 15q26.1 locus reduce FES expression in monocytes and that FES depletion results in larger atherosclerotic plaques with more monocytes/macrophages and smooth muscle cells. This study is the first demonstration that FES plays a protective role against atherosclerosis and suggests that enhancing FES activity could be a potentially novel therapeutic approach for CAD intervention.
Collapse
Affiliation(s)
- Elisavet Karamanavi
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - David G. McVey
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Sander W. van der Laan
- Central Diagnostic Laboratory, University of Utrecht, The Netherlands (S.W.v.d.L., G.P.)
| | - Paulina J. Stanczyk
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Gavin E. Morris
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Yifan Wang
- Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Y.W., H.Y., S.Y.)
| | - Wei Yang
- Shantou University Medical College, China (W.Y., J.C., S.Y.)
| | - Kenneth Chan
- William Harvey Research Institute, Queen Mary University of London, United Kingdom (K.C., R.N.P., J.L., X.Z., Q.X.)
| | - Robin N. Poston
- William Harvey Research Institute, Queen Mary University of London, United Kingdom (K.C., R.N.P., J.L., X.Z., Q.X.)
| | - Jun Luo
- William Harvey Research Institute, Queen Mary University of London, United Kingdom (K.C., R.N.P., J.L., X.Z., Q.X.)
| | - Xinmiao Zhou
- William Harvey Research Institute, Queen Mary University of London, United Kingdom (K.C., R.N.P., J.L., X.Z., Q.X.)
| | - Peng Gong
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Peter D. Jones
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Junjun Cao
- Shantou University Medical College, China (W.Y., J.C., S.Y.)
| | - Renata B. Kostogrys
- Department of Human Nutrition, University of Agriculture in Kraków, Poland (R.B.K.)
| | - Tom R. Webb
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Gerard Pasterkamp
- Central Diagnostic Laboratory, University of Utrecht, The Netherlands (S.W.v.d.L., G.P.)
| | - Haojie Yu
- Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Y.W., H.Y., S.Y.)
| | - Qingzhong Xiao
- William Harvey Research Institute, Queen Mary University of London, United Kingdom (K.C., R.N.P., J.L., X.Z., Q.X.)
| | - Peter A. Greer
- Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Canada (P.A.G.)
| | - Emma J. Stringer
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Nilesh J. Samani
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
| | - Shu Ye
- Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (E.K., D.G.M., P.J.S., G.E.M., P.G., P.D.J., T.R.W., E.J.S., N.J.S., S.Y.)
- Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Y.W., H.Y., S.Y.)
- Shantou University Medical College, China (W.Y., J.C., S.Y.)
| |
Collapse
|
2
|
Agarwal P, Cole LK, Chandrakumar A, Hauff KD, Ravandi A, Dolinsky VW, Hatch GM. Phosphokinome Analysis of Barth Syndrome Lymphoblasts Identify Novel Targets in the Pathophysiology of the Disease. Int J Mol Sci 2018; 19:ijms19072026. [PMID: 30002286 PMCID: PMC6073761 DOI: 10.3390/ijms19072026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 07/06/2018] [Accepted: 07/09/2018] [Indexed: 12/25/2022] Open
Abstract
Barth Syndrome (BTHS) is a rare X-linked genetic disease in which the specific biochemical deficit is a reduction in the mitochondrial phospholipid cardiolipin (CL) as a result of a mutation in the CL transacylase tafazzin. We compared the phosphokinome profile in Epstein-Barr-virus-transformed lymphoblasts prepared from a BTHS patient with that of an age-matched control individual. As expected, mass spectrometry analysis revealed a significant (>90%) reduction in CL in BTHS lymphoblasts compared to controls. In addition, increased oxidized phosphatidylcholine (oxPC) and phosphatidylethanolamine (PE) levels were observed in BTHS lymphoblasts compared to control. Given the broad shifts in metabolism associated with BTHS, we hypothesized that marked differences in posttranslational modifications such as phosphorylation would be present in the lymphoblast cells of a BTHS patient. Phosphokinome analysis revealed striking differences in the phosphorylation levels of phosphoproteins in BTHS lymphoblasts compared to control cells. Some phosphorylated proteins, for example, adenosine monophosphate kinase, have been previously validated as bonafide modified phosphorylation targets observed in tafazzin deficiency or under conditions of reduced cellular CL. Thus, we report multiple novel phosphokinome targets in BTHS lymphoblasts and hypothesize that alteration in the phosphokinome profile may provide insight into the pathophysiology of BTHS and potential therapeutic targets.
Collapse
Affiliation(s)
- Prasoon Agarwal
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Children's Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION), University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
| | - Laura K Cole
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
| | - Abin Chandrakumar
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Clinical Research Unit, Children's Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada.
| | - Kristin D Hauff
- Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada.
| | - Amir Ravandi
- Physiology and Pathophysiology, University of Manitoba, St. Boniface Hospital Research Center, Winnipeg, MB R2H 2A6, Canada.
| | - Vernon W Dolinsky
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Children's Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION), University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
| | - Grant M Hatch
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Diabetes Research Envisioned and Accomplished in Manitoba (DREAM), Children's Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada.
- Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
| |
Collapse
|